1 School of Medicine, University of California , San Francisco, San Francisco, California.
2 South American Program in HIV Prevention Research, Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine , Los Angeles, California.
LGBT Health. 2017 Oct;4(5):371-375. doi: 10.1089/lgbt.2017.0057. Epub 2017 Sep 6.
Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence.
This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA.
Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns.
Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.
激素疗法（HT）和抗逆转录病毒疗法（ART）对感染艾滋病毒的跨性别女性（TW）都具有挽救生命的作用，但每种疗法都有副作用和潜在的药物相互作用（DDI）。我们评估了对 HT-ART 相互作用的担忧如何影响治疗依从性。
本研究使用了加利福尼亚州洛杉矶的 TW（n=87）的横断面调查。
54%的 TW 患有 HIV；64%的 TW 使用 HT。仅有 49%的 HIV 感染者与提供者讨论过 ART-HT DDI；40%的 TW 报告由于 DDI 问题，未按规定服用 ART（12%）、HT（12%）或两者（16%）。
不完美的 HT/ART 使用和有限的提供者沟通表明需要更好地整合 HT-ART。
